The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics
- 3 September 2020
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 303 (2) , 455-461
Abstract
Purpose The long-term risk of thrombosis after pregnancy in women with purely obstetric antiphospholipid syndrome (OAPS) is not well defined. The current study’s primary outcome was to evaluate the incidence and characteristics of the first thrombotic event in OAPS, identifying the risk factors for thrombosis in OAPS was its secondary one. Methods Patients with purely OAPS were consecutively enrolled between September 1999 and September 2019. Subjects without a history of pregnancy morbidity or thrombosis but with persistent positivity for one or more antiphospholipid antibodies (aPL carriers) made up the control group. The study groups included 94 OAPS patients and 124 aPL carriers who were matched for clinical and laboratory parameters. Results An event rate of 0.49/100 patient years was registered in OAPS patients during a mean follow-up of 8.7 years ± 5.5 SD. Kaplan–Meier survival analysis revealed that the cumulative incidence of thromboembolic events was not significantly different in OAPS patients vs aPL carriers. Arterial thrombosis and cerebrovascular events were the more frequent types of vascular involvement in the two groups. As far as risk factors for thrombosis were concerned, the presence of lupus anticoagulant significantly prevailed in both thrombotic OAPS patients and thrombotic aPL carriers with respect to purely OAPS patients and aPL carriers who did not develop thrombosis (p = 0.01 and p = 0.00, respectively). Conclusion Just as for aPL carriers, closer monitoring and possibly, a pharmacological prophylaxis should be reserved for OAPS patients at highest risk of developing the first thrombotic event.Keywords
This publication has 21 references indexed in Scilit:
- Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodiesArthritis & Rheumatism, 2012
- Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective studyBlood, 2011
- Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control studyRheumatology, 2011
- Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up studyAnnals of the Rheumatic Diseases, 2011
- Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patientsLupus, 2011
- Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsiaThrombosis and Haemostasis, 2011
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classificationJournal of Thrombosis and Haemostasis, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Treatment of antiphospholipid syndrome in pregnancy—a systematic review of randomized therapeutic trialsThrombosis Research, 2004